Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

93 Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen (HBeAg)-Negative Patients Achieved Undetectable Viral Load by Week 48 of Re-Treatment

PRINCETON, N.J., April 13, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced data from a cohort of nucleoside-naive HBeAg-negative chronic hepatitis B patients (ETV-027/901, n=99). These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with BARACLUDE(R) (entecavir) achieved viral suppression and liver enzyme (ALT) normalization when re- treated for 48 weeks with BARACLUDE. The study results were presented at the 42nd Annual Meeting of the European Association for the Study of Liver Diseases (EASL) in Barcelona, Spain.

In this cohort, 93 percent of patients who were re-treated with BARACLUDE had undetectable viral load - the level of the hepatitis B virus in the blood - (HBV DNA <300 copies/mL, measured by a common assay - polymerase chain reaction or PCR) and 83 percent achieved liver enzyme normalization (ALT less than or equal to 1xULN) after 48 weeks of therapy.

"This study showed that when treated again with BARACLUDE for 48 weeks, patients achieved responses similar to those seen prior to treatment interruption, with safety results consistent with previously reported experience," said Hakan Senturk, MD, of the Ist.Univ.Cerrahpasa Tip Fak, Istanbul, Turkey.

No deaths or treatment discontinuations due to adverse events were reported in this cohort. The most common adverse events occurring in greater than 10 percent of patients were abdominal pain, fatigue, upper respiratory tract infection, nasopharyngitis, increased ALT, arthralgia, and headache.

About the Nucleoside-Naive HBeAg-Negative BARACLUDE(R) (entecavir) Re- Treatment Cohort

This analysis evaluated BARACLUDE(R) (entecavir) in nucleoside-naive chronic HBeAg-negative patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:8/1/2014)... , August 1, 2014 ... by Type (Traditional Wound Closure, Anti infective), Basic (Films, ... Skin & Skin Substitutes), Pressure Relief Devices, NPWT) ... global Wound Care Market is expected to reach ... 2014, growing at a CAGR of 3.2% from ...
(Date:8/1/2014)... Pa. , Aug. 1, 2014 Inovio ... will host a conference call to report its second ... at 9:00 AM ET. CEO Dr. J. Joseph ... discuss second quarter earnings, provide a corporate update, and ... will include clinical development plans for VGX-3100, Inovio,s immune ...
(Date:7/31/2014)... 2014  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
Breaking Medicine Technology:Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... plays a central role in regulating appetite and whole-body ... the brain,s control of food intake and body weight, ... has been unclear. A new study in ... PPARγ activity in a type of neuron known as ... to high-fat diet. Sabrina Diano and colleagues at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Stryker ... wake of the 2012 Rejuvenate and ABG II ... in New Jersey’s Bergen County Superior Court, Bernstein ... the proceeding, the Court has issued a ... any and all hard copy and electronic materials ...
(Date:8/1/2014)... at University Hospitals Rainbow Babies & Children,s Hospital (UH ... risk for death on a commercial airline flight. The ... January 2010 and June 2013 and found 90 percent ... 2. , The study was conducted in partnership ... in-flight pediatric fatality onboard commercial airline flights worldwide. Through ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... for independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen ... equipped with practices and resources to enhance patient ... leaders focused on critical issues to give independent ... and grow. , ThoughtSpot show attendance experienced ...
(Date:8/1/2014)... of a cancer diagnosis may improve health outcomes for ... by a researcher at the University of Houston (UH). ... intervention is the writing instruction. Otherwise, writing is just ... journal can be therapeutic, but oftentimes we don,t get ... not," said Qian Lu, assistant professor and director of ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3
... University shows for the first time that the brain ... food and drugs - offering insights into our propensity ... boxing and football. , The research will be published ... Psychopharmacology. , Aggression occurs among virtually all vertebrates and ...
... Routing cue works like a Zip code helps deliver mail, ... researchers have found a way to modify the surface of ... advance that may prove useful in many areas of stem ... at Brigham and Women,s Hospital in Boston modified the surface ...
... $25.5 Million Investment in Detroit - Opens Thursday, DETROIT, ... of Detroit Mercy will be opening a new School of ... giving back to,the City of Detroit. The new wireless facility ... country., Over 261,000 square feet, the School,s new location ...
... Recognising people, objects or animals by the sound they make ... take for granted. But very similar objects can physically make ... subtle clues about the identity and source of the sound. ... (BBSRC) are working out how the human ear and the ...
... into ,skeleton, of animal organ was beating in just ... An organ-building biotechnology that could create transplantable hearts using ... laboratory tests, researchers report. , The technique, called whole ... tissue, according to a report in the Jan. 13 ...
... Fortune 500 Executive Driving Global Breast Cancer Leader,s Promise ... Quickly, End Breast Cancer Forever, ATLANTA, Jan. 12 ... Cure, the global leader in the fight to end breast,cancer ... the,16th annual Trumpet Awards event in Atlanta with a ,High ...
Cached Medicine News:Health News:Aggression as rewarding as sex, food and drugs 2Health News:Stem Cells Modified to Home in Where They're Needed 2Health News:University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 2Health News:University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 3Health News:Lend me your ears -- and the world will sound very different 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
The K-ASSAY hs-CRP Control Set is intended to be used as a consistent test sample of known concentrations for monitoring the performance of hs-CRP (high sensitive C-Reactive Protein) immunoturbimetri...
Medicine Products: